Dividend Distribution - The company plans to distribute a cash dividend of 0.70 CNY per 10 shares, totaling approximately 27.81 million CNY, which accounts for 29.86% of the net profit attributable to shareholders for the first half of 2024[2]. - The total share capital of the company is 400 million shares, with 397,286,124 shares available for dividend distribution after accounting for repurchased shares[2]. - The company is focused on enhancing shareholder returns through increased dividend frequency based on actual performance[2]. - The company commits to a cash dividend policy where at least 10% of the distributable profit will be distributed in cash, with a cumulative distribution of no less than 30% of the average annual distributable profit over any three consecutive fiscal years[96]. - In mature stages without significant capital expenditure, the cash dividend proportion should be at least 80% of the profit distribution; if there are major expenditures, it should be at least 40%[96]. Financial Performance - The company's operating revenue for the first half of 2024 was approximately RMB 750.54 million, a decrease of 6.81% compared to RMB 805.39 million in the same period last year[14]. - The net profit attributable to shareholders for the first half of 2024 was approximately RMB 93.13 million, down 16.67% from RMB 111.76 million in the previous year[14]. - The net cash flow from operating activities increased by 148.45% to approximately RMB 144.73 million, compared to RMB 58.25 million in the same period last year[14]. - The company's total assets as of June 30, 2024, were approximately RMB 5.10 billion, a slight decrease of 0.03% from RMB 5.10 billion at the end of the previous year[14]. - The basic earnings per share for the first half of 2024 were RMB 0.23, a decrease of 17.86% from RMB 0.28 in the same period last year[15]. Research and Development - The R&D expenditure accounted for 8.48% of operating revenue, an increase of 0.82 percentage points compared to 7.66% in the previous year[15]. - The total R&D investment for the current period is approximately ¥63.65 million, an increase of 3.13% compared to ¥61.72 million in the previous year[33]. - The company has established a complete and mature R&D technology system, emphasizing independent innovation and collaboration with medical institutions and clinical doctors[22]. - The company has filed for 34 new patents this period, with 17 patents granted, bringing the cumulative totals to 501 applications and 377 granted[31]. - The company is focusing on innovation in orthopedic products, driven by advancements in medical and material sciences, to meet the demand for personalized and minimally invasive solutions[20]. Market and Industry Trends - The population aged 65 and above in China reached 217 million, accounting for 15.4% of the total population, indicating a growing market for orthopedic medical devices[19]. - Per capita disposable income in China increased by 5.4% to 20,733 CNY, while per capita healthcare spending rose by 4.2% to 1,271 CNY, reflecting a strong demand for healthcare services[20]. - The orthopedic implant market is expected to expand significantly due to the aging population and increasing awareness of health and wellness among residents[20]. - The implementation of centralized procurement for orthopedic implants has stabilized, with domestic brands gaining a larger market share[20]. - The company is actively exploring new fields in orthopedic treatment, including neurosurgery and digital orthopedics, to provide comprehensive solutions for orthopedic diseases[48]. Corporate Governance and Compliance - The report indicates that the financial statements have not been audited, and the management has confirmed the accuracy and completeness of the financial report[3]. - The company has not reported any non-operational fund occupation by controlling shareholders or related parties[3]. - There are no special arrangements for corporate governance or significant matters affecting the company[3]. - The company has established a mechanism for environmental protection and has implemented measures to manage waste and emissions effectively[64]. - The company has committed to ensuring the authenticity and completeness of its prospectus and will bear compensation responsibilities if any discrepancies are found[72]. Risk Management - The company has outlined major risks and corresponding mitigation strategies in the report, emphasizing the importance of investor awareness regarding investment risks[3]. - The company is focusing on enhancing its R&D team stability and protecting core technologies through improved confidentiality measures and incentive mechanisms[49]. - The company will actively manage risks associated with fundraising projects to protect investor interests[92]. - The company has committed to compensating investors for any losses incurred due to violations of commitments by its directors and senior management[102]. - The company will take measures to disclose any inability to fulfill commitments due to uncontrollable factors and will seek to protect investor interests[102]. Shareholder Relations - The company will ensure that minority shareholders have the opportunity to express their opinions and that their legal rights are fully protected[98]. - The company will communicate with shareholders, particularly minority shareholders, through various channels to gather opinions on the cash dividend proposal[97]. - The company will establish an investor compensation fund if necessary to address direct economic losses suffered by investors[100]. - The company will propose supplementary or alternative commitments to protect investor rights in case of unfulfilled commitments[89]. - The company emphasizes the protection of small and medium-sized investors' interests in compensation processes[90]. Financial Management - The company has approved the use of up to RMB 950 million of temporarily idle raised funds for cash management, with a balance of RMB 908.09 million at the end of the reporting period[116]. - The company reported a total related party transaction amount of 42.22 million yuan for sales, 35.63 million yuan for purchases, and 7.16 million yuan for deposits, all priced at market rates[106]. - The company has committed to reducing related party transactions during the tenure of its controlling shareholder, ensuring no illegal occupation of funds or assets[103]. - The company has established and strictly implemented internal environmental management standards, ensuring that pollutant emissions comply with relevant standards, with no major environmental accidents reported during the reporting period[65]. - The company has undergone significant management changes, including the election of Chen Min as the new chairman and the appointment of new non-independent directors[60][62]. Financial Reporting and Accounting - The company prepares financial statements based on actual transactions and events in accordance with the accounting standards issued by the Ministry of Finance, ensuring a true and complete reflection of its financial status and operating results[157]. - The company's accounting policies and estimates applied comply with the relevant accounting standards, ensuring the financial statements accurately reflect the company's financial condition and cash flows[159]. - The company assesses control over investees based on the ability to influence returns and decision-making, ensuring all subsidiaries are included in the consolidated financial statements[167]. - The company recognizes the income from the disposal of equity investments in subsidiaries based on the difference between the disposal proceeds and the share of net assets and goodwill at the time of loss of control[170]. - The company uses observable inputs for fair value measurement when available, and applies valuation techniques when active market prices are not present[186].

重要内容提示： 截至 2024 年 7 月 31 日，山东威高骨科材料股份有限公司（以下简称"公 司"）通过上海证券交易所交易系统以集中竞价交易方式已累计回购公司股份 2,231,056 股，占公司总股本 400,000,000.00 股的比例为 0.558%，回购成交的 最高价为 42.40 元/股，最低价为 18.88 元/股，支付的资金总额为人民币 69,962,465.18 元（不含交易费用）。 证券代码：688161 证券简称：威高骨科 公告编号：2024-037 山东威高骨科材料股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律 监管指引第 7 号——回购股份》等相关规定及公司回购股份方案，在回购期限内 根据市场情况择机做出回购决策并予以实施，同时根据回购进展情况及时履行信 息披露义务，敬请广大投资者注意投资风险。 特此公告。 一、回购股份的基本情况 山东威高骨科材料股份有限公司董事会 2 ...

Summary of Weigao Orthopedics Conference Call Company Overview - **Company**: Weigao Orthopedics - **Industry**: Medical Devices, specifically Orthopedic Instruments - **Context**: The call discusses the company's recent performance and outlook in the context of the orthopedic industry in China, particularly following recent price adjustments and market changes due to centralized procurement policies. Key Points Company Performance - **Q2 Performance**: The company reported a strong growth phase in Q2, with a notable increase in surgical implants in the spine segment exceeding 30% year-on-year, although revenue in this segment saw a decline of over 10% due to the impact of centralized procurement [4][7]. - **Trauma Segment**: The trauma segment experienced a 20% increase in surgical implants, while the joint segment maintained stable surgical volumes with over 10% revenue growth due to price increases following the second round of joint procurement [5][6]. - **Overall Revenue Growth**: The company achieved year-on-year revenue growth in Q2, despite a slight decline in overall revenue for the first half of the year due to the impact of centralized procurement on the spine segment [6][7]. Market Dynamics - **Centralized Procurement Impact**: The company indicated that the worst impacts of centralized procurement are behind them, with expectations for a significant performance turnaround in the second half of the year [8][9]. - **Industry Recovery**: The orthopedic industry is recovering from previous disruptions, with surgical volumes returning to normal levels. The company has adapted to the new procurement environment, with 80% of sales now under centralized procurement [11][12]. Pricing Strategy - **Price Adjustments**: The company has begun to increase prices in the joint segment following the second round of procurement, with expectations for a 70% increase in pricing for certain products compared to previous rounds [19][20]. - **Future Pricing Trends**: The pricing strategy is expected to stabilize, with a more predictable environment for future procurement rounds anticipated [20][21]. International Expansion - **Overseas Market Strategy**: The company is focusing on expanding its international presence, with plans to enhance its product offerings in regions like Europe and Southeast Asia. The overseas revenue is projected to grow by 35% year-on-year [22][23]. - **Regulatory Approvals**: The company is actively working on obtaining necessary certifications for its products in international markets, which is expected to contribute significantly to revenue in the coming years [24][25]. Management Insights - **Operational Improvements**: The company has implemented more rigorous data analysis and management practices, leading to improved profit margins, with a target net profit margin of over 15% for the year [28][29]. - **Strategic Focus**: The management has identified three key growth areas: minimally invasive surgery, sports injury treatment, and regenerative rehabilitation, which are expected to drive future growth [30][31]. Investor Relations - **Share Buyback Plans**: The company has resumed its share buyback program, which is intended to support stock price stability and employee stock ownership plans [47][48]. - **Long-term Outlook**: The management expressed confidence in the company's ability to navigate the current market challenges and achieve sustainable growth, supported by strategic partnerships and operational efficiencies [72][73]. Additional Insights - **Channel Inventory Management**: The company has successfully managed channel inventory levels, ensuring that stock levels are normalized and aligned with market demand [16][17]. - **Competitive Landscape**: The company is positioned well against competitors, with a focus on maintaining quality and expanding market share despite pricing pressures from centralized procurement [39][40]. This summary encapsulates the key discussions and insights from the Weigao Orthopedics conference call, highlighting the company's performance, market dynamics, pricing strategies, international expansion efforts, and management's strategic focus for future growth.

关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 截至 2024 年 6 月 30 日，山东威高骨科材料股份有限公司（以下简称"公 司"）通过上海证券交易所交易系统以集中竞价交易方式已累计回购公司股份 1,597,266 股，占公司总股本 400,000,000.00 股的比例为 0.399%，回购成交的 最高价为 42.40 元/股，最低价为 28.59 元/股，支付的资金总额为人民币 57,460,342.24 元（不含交易费用）。 一、回购股份的基本情况 2023 年 8 月 28 日，公司召开第三届董事会第四次会议，审议通过了《关于 以集中竞价交易方式回购公司股份预案的议案》，同意公司以自有资金通过上海 证券交易所交易系统以集中竞价交易方式回购公司已发行的部分人民币普通股 股票，用于员工持股及/或股权激励计划。公司拟用于本次回购的资金总额不低 于人民币 6,000 万元，不超过人民币 1.2 亿元（含），回购价格为不超过人民币 50 元/股（含），回购期限 ...

山东威高骨科材料股份有限公司 2023 年年度权益分派实施公 告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 每股现金红利 0.12048 元 证券代码：688161 证券简称：威高骨科 公告编号：2024-035 相关日期 | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2024/7/4 | 2024/7/5 | 2024/7/5 | 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司 2024 年 4 月 29 日的 2023 年年度股东大会审议通过。 二、 分配方案 1. 发放年度：2023 年年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 （山东威高骨科材料股份有限公司回购专用证券账户除外）。 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份（2023 年 12 月修订）》等有 ...

华泰联合证券有限责任公司 关于山东威高骨科材料股份有限公司 差异化分红事项的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合证券"或"保荐机构"）作为 山东威高骨科材料股份有限公司（以下简称"威高骨科"、"公司"或"发行人"）首 次公开发行股票的保荐机构，根据《中华人民共和国公司法》《中华人民共和国证券 法》及《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等法律法规 的规定，对威高骨科 2023 年度利润分配所涉及的差异化分红（以下简称"本次差异 化分红"）事项进行了核查，核查情况如下： 一、本次差异化分红的原因 2023 年 8 月 28 日，公司召开第三届董事会第四次会议，审议通过了《关于以 集中竞价交易方式回购公司股份预案的议案》，同意公司以自有资金通过上海证券交 易所交易系统以集中竞价交易方式回购公司已发行的部分人民币普通股股票，用于 员工持股及/或股权激励计划。公司拟用于本次回购的资金总额不低于人民币 6,000 万元，不超过人民币 1.2 亿元（含），回购价格为不超过人民币 50 元/股（含），回购 期限为自公司董事会审议通过本次回购方案之日起 12 个月内。 截止目前，公司已 ...

Financial Performance - The company's total revenue for 2023 was approximately ¥1.28 billion, a decrease of 37.63% compared to ¥2.06 billion in 2022[32]. - Net profit attributable to shareholders for 2023 was ¥112.32 million, down 81.30% from ¥600.70 million in 2022[32]. - The basic earnings per share for 2023 was ¥0.28, reflecting an 81.33% decline from ¥1.50 in 2022[33]. - The company experienced a 27.83% decrease in sales volume and a 35.29% drop in revenue year-on-year for 2023[31]. - In Q1 2024, sales volume increased by 61.54% and revenue rose by 82.34% compared to the same quarter in 2023, driven by the launch of new products[31]. - The company's operating revenue for the reporting period was 1,283.55 million yuan, a decrease of 774.42 million yuan compared to the same period last year, primarily due to the impact of centralized procurement leading to a decline in ex-factory prices and channel inventory adjustments[90]. - The company's gross profit margin in the medical device manufacturing sector decreased by 10.07 percentage points to 66.51% compared to the previous year, with revenue from spinal products down by 48.49%, trauma products down by 53.89%, and joint products down by 35.29%[92]. - The net cash flow from operating activities was 119.44 million yuan, a decrease of 38.91 million yuan compared to the previous year, primarily due to reduced cash receipts from sales of goods and services[91]. - The company reported a significant decline in net profit due to the effects of centralized procurement pricing policies, with a total revenue of ¥128.35 million for the year[37]. Market Trends and Opportunities - The orthopedic medical device industry is experiencing significant growth driven by an aging population, increased healthcare spending, and rising public health awareness, indicating a strong market potential for orthopedic implants[15]. - The population aged 65 and above in China reached 210 million in 2022, accounting for 14.9% of the total population, an increase of 0.7 percentage points from 2021, indicating a growing market for orthopedic surgeries due to aging demographics[137]. - The orthopedic surgery market is expected to maintain stable growth due to the increasing incidence of degenerative diseases and rising demand for sports rehabilitation[137]. - The orthopedic surgery prevalence is anticipated to rise as the popularity of fitness activities leads to more sports-related injuries, increasing the demand for orthopedic procedures[137]. - The domestic orthopedic implant market is anticipated to expand significantly due to the increasing number of orthopedic disease patients and the current low penetration rate compared to foreign markets[166]. Product Development and Innovation - The company has established a complete and mature R&D technology system focused on orthopedic implant medical devices, emphasizing independent innovation and collaboration with medical institutions[10]. - The company is focusing on innovative technologies such as 3D printing for personalized orthopedic solutions, which enhances surgical precision and meets customized medical needs[17]. - Research and development of biodegradable materials is a key focus, with the potential to become a mainstream direction in orthopedic products, providing new profit growth points for the company[19]. - The integration of surgical robots with augmented reality and 5G technology is expanding the application scenarios for orthopedic surgeries, enhancing the capabilities of medical professionals[19]. - The company is advancing its digital orthopedic treatment methods, leveraging artificial intelligence to improve preoperative planning, intraoperative guidance, and postoperative recovery processes[20]. - The company has developed proprietary technologies such as the hook-shaped trapezoidal thread technology, which significantly improves the strength and safety of spinal screws, increasing the failure torque by nearly 50% compared to similar products[21]. - The new embedded saddle-shaped compression ring technology is being utilized in spinal fixation systems, enhancing the assembly process and overall product reliability[21]. - The company has introduced innovative products such as the PRP preparation kit, which is the first domestic brand to be launched in the market, ensuring high platelet recovery rates[48]. - The company is developing new products including ultrasound-enhanced puncture needles and Class III endoscopic surgical electrodes, expected to be certified in 2023 and 2024[162]. Sales and Distribution Strategy - The sales model primarily consists of distribution, with distributors responsible for channel expansion, customer maintenance, and professional support during the sales process[12]. - The company has enhanced market coverage through a nationwide logistics and distribution system, ensuring comprehensive service to reporting hospitals and increasing the share of external surgeries[40]. - The company is actively integrating its distribution network to ensure alignment with overall strategy and improve market share stability[63]. - The company has established partnerships with over 2,300 distributors, covering more than 5,000 terminal medical institutions nationwide[80]. - The company's domestic revenue accounted for 95.30% of total revenue, with distribution, delivery, and direct sales accounting for 77.19%, 15.71%, and 7.10% of total revenue, respectively[93]. Research and Development Investment - Research and development expenses accounted for 10.14% of total revenue in 2023, an increase of 4.42 percentage points from 5.72% in 2022[33]. - The total R&D investment amounted to ¥130,195,414.65, representing a year-over-year increase of 10.66%[50]. - R&D investment accounted for 5.72% of operating revenue, an increase of 4.42 percentage points compared to the previous year[50]. - The company has accumulated 66 domestic invention patents and 2 overseas invention patents, indicating a strong R&D capability[58]. - The company is focusing on digital transformation in lean production, significantly improving operational efficiency[41]. Regulatory and Compliance - The company has obtained ISO9001 and ISO13485 quality management system certifications, ensuring product quality reliability and stability[81]. - The company has obtained 29 Class I product registration certificates, 17 Class II medical device registration certificates, and 31 Class III medical device registration certificates during the reporting period[49]. - As of the end of the reporting period, the company holds a total of 281 Class I product registration certificates, 39 Class II medical device registration certificates, and 133 Class III medical device registration certificates[49]. Strategic Goals and Future Outlook - The company is focused on the orthopedic sector, aiming to become a global leader in orthopedic consumables and innovative medical technology, with a commitment to continuous innovation and international expansion[139]. - The company plans to leverage its R&D capabilities, production capacity, and financial resources to further increase market share as volume-based procurement continues to advance[138]. - The overall market concentration in the orthopedic industry is expected to increase as leading domestic enterprises enhance their competitive advantages[138]. - The company is committed to becoming a first-class supplier of orthopedic consumables, focusing on technological innovation and comprehensive solutions[139].

关于对山东威高骨科材料股份有限公司 2023 年年度报告的信息披露监管问询函 的回复 大华核字[2024]0011014326 号 大 华 会 计 师 事 务 所 (特 殊 普 通 合 伙 ) Da Hua Certified Public Accountants（Special General Partnership） 关于对山东威高骨科材料股份有限公司 2023 年年度报告的信息披露监管问询函的回复 目 录 页 次 一、 关于对山东威高骨科材料股份有限公司2023 年年度报告的信息披露监管问询函的回复 1-15 大华会计师事务所（特殊普通合伙） 北京市海淀区西四环中路 16 号院 7 号楼 12 层[100039] 电话：86(10)58350011 传真：86(10)58350006 www.dahua-cpa.com 关 于 对 山 东 威 高 骨 科 材 料 股 份 有 限 公 司 20 2 3 年 年 度 报 告 的 信 息 披 露 监 管 问 询 函 的 回 复 大华核字[2024]0011014326 号 上海证券交易所科创板公司管理部： 贵单位《关于对山东威高骨科材料股份有限公司 2023 ...

华泰联合证券有限责任公司 关于山东威高骨科材料股份有限公司 2023 年年报问询函的核查意见 上海证券交易所： 贵所出具的《关于山东威高骨科材料股份有限公司 2023 年年度报告的信息披 露监管问询函》（以下简称"问询函"）已收悉。华泰联合证券有限责任公司作为山 东威高骨科材料股份有限公司（以下简称"威高骨科"、"公司"）持续督导的保荐 机构，对问询函所列问题认真进行了逐项落实，现对涉及持续督导保荐机构发表意 见的问题进行回复，请予审核。回复中楷体加粗部分为公司《2023 年年度报告》 补充披露或修改的部分。 1 一、关于业务经营 1、年报披露，公司 2023 年度营业收入 128,354.92 万元，同比减少 37.63%； 归属母公司股东的净利润 11,231.50 万元，同比减少 81.30%；当期毛利率 66.51%，较上年减少 10.07 个百分点。其中，脊柱板块、创伤板块、关节板块营业 收入分别下降 48.49%、53.89%、35.29%，下滑主要原因为带量采购执行引起产品 出厂价格下降以及渠道存货补差给予进货价格折让影响。2024 年一季报披露，公 司 2024 年一季度营业收入 34,791 ...

证券代码：688161 证券简称：威高骨科 公告编号：2024-034 山东威高骨科材料股份有限公司 关于 2023 年年报问询函回复的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 山东威高骨科材料股份有限公司（以下简称"公司"或"威高骨科"）于 2024 年 6 月 12 日收到上海证券交易所科创板公司管理部下发的上证科创公函 【2024】0196 号《关于山东威高骨科材料股份有限公司 2023 年年度报告的信息 披露监管问询函》（以下简称"《问询函》"）。公司会同保荐机构华泰联合证券有 限责任公司（以下简称"华泰联合证券"或"保荐机构"）、年审会计师大华会计 师事务所(特殊普通合伙)（以下简称"会计师"）就《问询函》有关问题逐项进 行认真核查落实，现将有关问题回复如下： 一、关于业务经营 1、年报披露，公司 2023 年度营业收入 128,354.92 万元，同比减少 37.63%； 归属母公司股东的净利润 11,231.50 万元，同比减少 81.30%；当期毛利率 66.51%，较上年减少 10.07 个百 ...